Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Kidney Blood Press Res ; 40(5): 542-54, 2015.
Article in English | MEDLINE | ID: mdl-26501147

ABSTRACT

BACKGROUND/AIMS: The purpose of the present study was to compare the direct renin inhibitor aliskiren to the diuretic hydrochlorothiazide (HCTZ) in their ability to modulate renal tissue oxygenation in hypertensive patients. METHODS: 24 patients were enrolled in this randomized prospective study and 20 completed the protocol. Patients were randomly assigned to receive either aliskiren 150-300 mg/d or HCTZ 12.5 - 25 mg/d for 8 weeks. Renal oxygenation was measured by BOLD-MRI at weeks 0 and 8. BOLD-MRI was also performed before and after an i.v. injection of 20 mg furosemide at week 0 and at week 8. BOLD-MRI data were analyzed by measuring the oxygenation in 12 computed layers of the kidney enabling to asses renal oxygenation according to the depth within the kidney and by the classical method of regions of interest (ROI). RESULTS: The classical ROI analysis of the data showed no difference between the groups at week 8. The analysis of renal oxygenation according to the 12 layers method shows no significant difference between aliskiren and HCTZ at week 8 before administration of furosemide. However, within group analyses show that aliskiren slightly but not significantly increased oxygenation in the cortex and decreased medullary oxygenation whereas HCTZ induced a significant overall decrease in renal tissue oxygenation. With the same method of analysis we observed that the response to furosemide was unchanged in the HCTZ group at week 8 but was characterized by an increase in both cortical and medullary oxygenation in aliskiren-treated patients. Patients responding to aliskiren and HCTZ by a fall in systolic blood pressure of >10 mmHg improved their renal tissue oxygenation when compared to non-responders. CONCLUSION: With the classical method of evaluation using regions no difference were found between aliskiren and HCTZ on renal tissue oxygenation after 8 weeks. In contrast, with our new method that takes into account the entire kidney, within group analyses show that aliskiren slightly increases cortical and medullary renal tissue oxygenation in hypertensive patients whereas HCTZ decreases significantly renal oxygenation at trough.


Subject(s)
Amides/therapeutic use , Fumarates/therapeutic use , Hydrochlorothiazide/therapeutic use , Hypertension/drug therapy , Hypertension/metabolism , Kidney/metabolism , Renin/antagonists & inhibitors , Adult , Aged , Amides/pharmacology , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Female , Fumarates/pharmacology , Humans , Hydrochlorothiazide/pharmacology , Hypertension/diagnosis , Kidney/drug effects , Male , Middle Aged , Oxygen Consumption/drug effects , Oxygen Consumption/physiology , Prospective Studies , Single-Blind Method
2.
Pflugers Arch ; 467(12): 2413-21, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26089029

ABSTRACT

Interactions between sodium and calcium regulating systems are poorly characterized but clinically important. Parathyroid hormone (PTH) levels are increased shortly after furosemide treatment by an unknown mechanism, and this effect is blunted by the previous administration of a calcimimetic in animal studies. Here, we explored further the possible underlying mechanisms of this observation in a randomized crossover placebo-controlled study performed in 18 human males. Volunteers took either cinacalcet (60 mg) or placebo and received a 20 mg furosemide injection 3 h later. Plasma samples were collected at 15-min intervals and analyzed for intact PTH, calcium, sodium, potassium, magnesium, phosphate, plasma renin activity (PRA), and aldosterone up to 6 h after furosemide injection. Urinary electrolyte excretion was also monitored. Subjects under placebo presented a sharp increase in PTH levels after furosemide injection. In the presence of cinacalcet, PTH levels were suppressed and marginal increase of PTH was observed. No significant changes in electrolytes and urinary excretion were identified that could explain the furosemide-induced increase in PTH levels. PRA and aldosterone were stimulated by furosemide injection but were not affected by previous cinacalcet ingestion. Expression of NKCC1, but not NKCC2, was found in parathyroid tissue. In conclusion, our results indicate that furosemide acutely stimulates PTH secretion in the absence of any detectable electrolyte changes in healthy adults. A possible direct effect of furosemide on parathyroid gland needs further studies.


Subject(s)
Diuretics/pharmacology , Furosemide/pharmacology , Parathyroid Hormone/blood , Receptors, Calcium-Sensing/metabolism , Renin-Angiotensin System/drug effects , Renin/blood , Adolescent , Adult , Aldosterone/blood , Calcimimetic Agents/pharmacology , Calcium/blood , Cinacalcet/pharmacology , Diuretics/administration & dosage , Female , Furosemide/administration & dosage , Humans , Male , Middle Aged , Parathyroid Glands/metabolism , Solute Carrier Family 12, Member 1/genetics , Solute Carrier Family 12, Member 1/metabolism , Solute Carrier Family 12, Member 2/genetics , Solute Carrier Family 12, Member 2/metabolism
3.
PLoS One ; 9(4): e95895, 2014.
Article in English | MEDLINE | ID: mdl-24760031

ABSTRACT

Experimentally renal tissue hypoxia appears to play an important role in the pathogenesis of chronic kidney disease (CKD) and arterial hypertension (AHT). In this study we measured renal tissue oxygenation and its determinants in humans using blood oxygenation level-dependent magnetic resonance imaging (BOLD-MRI) under standardized hydration conditions. Four coronal slices were selected, and a multi gradient echo sequence was used to acquire T2* weighted images. The mean cortical and medullary R2* values ( = 1/T2*) were calculated before and after administration of IV furosemide, a low R2* indicating a high tissue oxygenation. We studied 195 subjects (95 CKD, 58 treated AHT, and 42 healthy controls). Mean cortical R2 and medullary R2* were not significantly different between the groups at baseline. In stimulated conditions (furosemide injection), the decrease in R2* was significantly blunted in patients with CKD and AHT. In multivariate linear regression analyses, neither cortical nor medullary R2* were associated with eGFR or blood pressure, but cortical R2* correlated positively with male gender, blood glucose and uric acid levels. In conclusion, our data show that kidney oxygenation is tightly regulated in CKD and hypertensive patients at rest. However, the metabolic response to acute changes in sodium transport is altered in CKD and in AHT, despite preserved renal function in the latter group. This suggests the presence of early renal metabolic alterations in hypertension. The correlations between cortical R2* values, male gender, glycemia and uric acid levels suggest that these factors interfere with the regulation of renal tissue oxygenation.


Subject(s)
Hypertension/metabolism , Kidney Cortex/metabolism , Kidney Medulla/metabolism , Magnetic Resonance Imaging/methods , Oxygen/blood , Renal Insufficiency, Chronic/metabolism , Administration, Intravenous , Adult , Aged , Case-Control Studies , Cell Hypoxia , Diuretics/administration & dosage , Female , Furosemide/administration & dosage , Humans , Hypertension/pathology , Kidney/anatomy & histology , Kidney/drug effects , Kidney/metabolism , Kidney Cortex/drug effects , Kidney Medulla/drug effects , Male , Middle Aged , Oxygen Consumption , Renal Insufficiency, Chronic/pathology
4.
Biomed Res Int ; 2013: 104892, 2013.
Article in English | MEDLINE | ID: mdl-23971019

ABSTRACT

BACKGROUND/AIMS: One of the causes of uncontrolled secondary hyperparathyroidism (sHPT) is patient's poor drug adherence. We evaluated the clinical benefits of an integrated care approach on the control of sHPT by cinacalcet. METHODS: Prospective, randomized, controlled, multicenter, open-label study. Fifty hemodialysis patients on a stable dose of cinacalcet were randomized to an integrated care approach (IC) or usual care approach (UC). In the IC group, cinacalcet adherence was monitored using an electronic system. Results were discussed with the patients in motivational interviews, and drug prescription adapted accordingly. In the UC group, drug adherence was monitored, but results were not available. RESULTS: At six months, 84% of patients in the IC group achieved recommended iPTH targets versus 55% in the UC group (P = 0.04). The mean cinacalcet taking adherence improved by 10.8% in the IC group and declined by 5.3% in the UC group (P = 0.02). Concomitantly, the mean dose of cinacalcet was reduced by 7.2 mg/day in the IC group and increased by 6.4 mg/day in the UC group (P = 0.03). CONCLUSIONS: The use of a drug adherence monitoring program in the management of sHPT in hemodialysis patients receiving cinacalcet improves drug adherence and iPTH control and allows a reduction in the dose of cinacalcet.


Subject(s)
Drug Monitoring/statistics & numerical data , Hyperparathyroidism, Secondary/drug therapy , Hyperparathyroidism, Secondary/epidemiology , Kidney Failure, Chronic/epidemiology , Kidney Failure, Chronic/rehabilitation , Medication Adherence/statistics & numerical data , Naphthalenes/therapeutic use , Calcimimetic Agents/therapeutic use , Causality , Cinacalcet , Comorbidity , Drug Monitoring/methods , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/prevention & control , Female , Humans , Male , Middle Aged , Prevalence , Risk Factors , Switzerland/epidemiology , Treatment Outcome
5.
Am J Hypertens ; 26(4): 527-34, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23467208

ABSTRACT

BACKGROUND: Higher nighttime blood pressure (BP) and the loss of nocturnal dipping of BP are associated with an increased risk for cardiovascular events. However, the determinants of the loss of nocturnal BP dipping are only beginning to be understood. We investigated whether different indicators of physical activity were associated with the loss of nocturnal dipping of BP. METHODS: We conducted a cross-sectional study of 103 patients referred for 24-hour ambulatory monitoring of BP. We measured these patients' step count (SC), active energy expenditure (AEE), and total energy expenditure simultaneously, using actigraphs. RESULTS: In our study population of 103 patients, most of whom were hypertensive, SC and AEE were associated with nighttime systolic BP in univariate (SC, r = -0.28, P < 0.01; AEE, r = -0.20, P = 0.046) and multivariate linear regression analyses (SC, coefficient beta = -5.37, P < 0.001; AEE, coefficient beta = -0.24, P < 0.01). Step count was associated with both systolic (r = 0.23, P = 0.018) and diastolic (r = 0.20, P = 0.045) BP dipping. Nighttime systolic BP decreased progressively across the categories of sedentary, moderately active, and active participants (125mm Hg, 116mm Hg, 112mm Hg, respectively; P = 0.002). The degree of BP dipping of BP increased progressively across the same three categories of activity (respectively 8.9%, 14.6%, and 18.6%, P = 0.002, for systolic BP and respectively 12.8%, 18.1%, and 22.2%, P = 0.006, for diastolic BP). CONCLUSIONS: Step count is continuously associated with nighttime systolic BP and with the degree of BP dipping independently of 24-hour mean BP. The combined use of an actigraph for measuring indicators of physical activity and a device for 24-hour measurement of ambulatory BP may help identify patients at increased risk for cardiovascular events in whom increased physical activity toward higher target levels may be recommended.


Subject(s)
Blood Pressure/physiology , Circadian Rhythm/physiology , Energy Metabolism/physiology , Adult , Aged , Blood Pressure Monitoring, Ambulatory , Cross-Sectional Studies , Female , Humans , Hypertension/physiopathology , Male , Middle Aged , Motor Activity , Sedentary Behavior , Walking/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...